Implementing ASCENT-04 Into Clinical Practice

If SG plus pembrolizumab becomes approved in the first-line metastatic TNBC setting, many clinicians anticipate shifting practice patterns to favor this regimen, given its promising efficacy. Key takeaways for academic centers include staying current with evolving data and integrating biomarker-driven pathways, while community practices and pharmacies should focus on operational readiness, toxicity management, and patient education to ensure safe, consistent delivery of these advanced therapies.